Cargando…
Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium
AIMS/HYPOTHESIS: The DIRECT (Diabetes Research on Patient Stratification) Study is part of a European Union Framework 7 Innovative Medicines Initiative project, a joint undertaking between four industry and 21 academic partners throughout Europe. The Consortium aims to discover and validate biomarke...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4018481/ https://www.ncbi.nlm.nih.gov/pubmed/24695864 http://dx.doi.org/10.1007/s00125-014-3216-x |
_version_ | 1782480074006593536 |
---|---|
author | Koivula, Robert W. Heggie, Alison Barnett, Anna Cederberg, Henna Hansen, Tue H. Koopman, Anitra D. Ridderstråle, Martin Rutters, Femke Vestergaard, Henrik Gupta, Ramneek Herrgård, Sanna Heymans, Martijn W. Perry, Mandy H. Rauh, Simone Siloaho, Maritta Teare, Harriet J. A. Thorand, Barbara Bell, Jimmy Brunak, Søren Frost, Gary Jablonka, Bernd Mari, Andrea McDonald, Tim J. Dekker, Jacqueline M. Hansen, Torben Hattersley, Andrew Laakso, Markku Pedersen, Oluf Koivisto, Veikko Ruetten, Hartmut Walker, Mark Pearson, Ewan Franks, Paul W. |
author_facet | Koivula, Robert W. Heggie, Alison Barnett, Anna Cederberg, Henna Hansen, Tue H. Koopman, Anitra D. Ridderstråle, Martin Rutters, Femke Vestergaard, Henrik Gupta, Ramneek Herrgård, Sanna Heymans, Martijn W. Perry, Mandy H. Rauh, Simone Siloaho, Maritta Teare, Harriet J. A. Thorand, Barbara Bell, Jimmy Brunak, Søren Frost, Gary Jablonka, Bernd Mari, Andrea McDonald, Tim J. Dekker, Jacqueline M. Hansen, Torben Hattersley, Andrew Laakso, Markku Pedersen, Oluf Koivisto, Veikko Ruetten, Hartmut Walker, Mark Pearson, Ewan Franks, Paul W. |
author_sort | Koivula, Robert W. |
collection | PubMed |
description | AIMS/HYPOTHESIS: The DIRECT (Diabetes Research on Patient Stratification) Study is part of a European Union Framework 7 Innovative Medicines Initiative project, a joint undertaking between four industry and 21 academic partners throughout Europe. The Consortium aims to discover and validate biomarkers that: (1) predict the rate of glycaemic deterioration before and after type 2 diabetes onset; (2) predict the response to diabetes therapies; and (3) help stratify type 2 diabetes into clearly definable disease subclasses that can be treated more effectively than without stratification. This paper describes two new prospective cohort studies conducted as part of DIRECT. METHODS: Prediabetic participants (target sample size 2,200–2,700) and patients with newly diagnosed type 2 diabetes (target sample size ~1,000) are undergoing detailed metabolic phenotyping at baseline and 18 months and 36 months later. Abdominal, pancreatic and liver fat is assessed using MRI. Insulin secretion and action are assessed using frequently sampled OGTTs in non-diabetic participants, and frequently sampled mixed-meal tolerance tests in patients with type 2 diabetes. Biosamples include venous blood, faeces, urine and nail clippings, which, among other biochemical analyses, will be characterised at genetic, transcriptomic, metabolomic, proteomic and metagenomic levels. Lifestyle is assessed using high-resolution triaxial accelerometry, 24 h diet record, and food habit questionnaires. CONCLUSIONS/INTERPRETATION: DIRECT will yield an unprecedented array of biomaterials and data. This resource, available through managed access to scientists within and outside the Consortium, will facilitate the development of new treatments and therapeutic strategies for the prevention and management of type 2 diabetes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00125-014-3216-x) contains peer-reviewed but unedited supplementary material, which is available to authorised users. |
format | Online Article Text |
id | pubmed-4018481 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-40184812014-05-13 Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium Koivula, Robert W. Heggie, Alison Barnett, Anna Cederberg, Henna Hansen, Tue H. Koopman, Anitra D. Ridderstråle, Martin Rutters, Femke Vestergaard, Henrik Gupta, Ramneek Herrgård, Sanna Heymans, Martijn W. Perry, Mandy H. Rauh, Simone Siloaho, Maritta Teare, Harriet J. A. Thorand, Barbara Bell, Jimmy Brunak, Søren Frost, Gary Jablonka, Bernd Mari, Andrea McDonald, Tim J. Dekker, Jacqueline M. Hansen, Torben Hattersley, Andrew Laakso, Markku Pedersen, Oluf Koivisto, Veikko Ruetten, Hartmut Walker, Mark Pearson, Ewan Franks, Paul W. Diabetologia Article AIMS/HYPOTHESIS: The DIRECT (Diabetes Research on Patient Stratification) Study is part of a European Union Framework 7 Innovative Medicines Initiative project, a joint undertaking between four industry and 21 academic partners throughout Europe. The Consortium aims to discover and validate biomarkers that: (1) predict the rate of glycaemic deterioration before and after type 2 diabetes onset; (2) predict the response to diabetes therapies; and (3) help stratify type 2 diabetes into clearly definable disease subclasses that can be treated more effectively than without stratification. This paper describes two new prospective cohort studies conducted as part of DIRECT. METHODS: Prediabetic participants (target sample size 2,200–2,700) and patients with newly diagnosed type 2 diabetes (target sample size ~1,000) are undergoing detailed metabolic phenotyping at baseline and 18 months and 36 months later. Abdominal, pancreatic and liver fat is assessed using MRI. Insulin secretion and action are assessed using frequently sampled OGTTs in non-diabetic participants, and frequently sampled mixed-meal tolerance tests in patients with type 2 diabetes. Biosamples include venous blood, faeces, urine and nail clippings, which, among other biochemical analyses, will be characterised at genetic, transcriptomic, metabolomic, proteomic and metagenomic levels. Lifestyle is assessed using high-resolution triaxial accelerometry, 24 h diet record, and food habit questionnaires. CONCLUSIONS/INTERPRETATION: DIRECT will yield an unprecedented array of biomaterials and data. This resource, available through managed access to scientists within and outside the Consortium, will facilitate the development of new treatments and therapeutic strategies for the prevention and management of type 2 diabetes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00125-014-3216-x) contains peer-reviewed but unedited supplementary material, which is available to authorised users. Springer Berlin Heidelberg 2014-04-04 2014 /pmc/articles/PMC4018481/ /pubmed/24695864 http://dx.doi.org/10.1007/s00125-014-3216-x Text en © The Author(s) 2014 https://creativecommons.org/licenses/by/4.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Article Koivula, Robert W. Heggie, Alison Barnett, Anna Cederberg, Henna Hansen, Tue H. Koopman, Anitra D. Ridderstråle, Martin Rutters, Femke Vestergaard, Henrik Gupta, Ramneek Herrgård, Sanna Heymans, Martijn W. Perry, Mandy H. Rauh, Simone Siloaho, Maritta Teare, Harriet J. A. Thorand, Barbara Bell, Jimmy Brunak, Søren Frost, Gary Jablonka, Bernd Mari, Andrea McDonald, Tim J. Dekker, Jacqueline M. Hansen, Torben Hattersley, Andrew Laakso, Markku Pedersen, Oluf Koivisto, Veikko Ruetten, Hartmut Walker, Mark Pearson, Ewan Franks, Paul W. Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium |
title | Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium |
title_full | Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium |
title_fullStr | Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium |
title_full_unstemmed | Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium |
title_short | Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium |
title_sort | discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the imi direct consortium |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4018481/ https://www.ncbi.nlm.nih.gov/pubmed/24695864 http://dx.doi.org/10.1007/s00125-014-3216-x |
work_keys_str_mv | AT koivularobertw discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium AT heggiealison discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium AT barnettanna discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium AT cederberghenna discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium AT hansentueh discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium AT koopmananitrad discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium AT ridderstralemartin discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium AT ruttersfemke discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium AT vestergaardhenrik discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium AT guptaramneek discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium AT herrgardsanna discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium AT heymansmartijnw discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium AT perrymandyh discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium AT rauhsimone discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium AT siloahomaritta discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium AT teareharrietja discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium AT thorandbarbara discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium AT belljimmy discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium AT brunaksøren discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium AT frostgary discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium AT jablonkabernd discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium AT mariandrea discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium AT mcdonaldtimj discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium AT dekkerjacquelinem discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium AT hansentorben discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium AT hattersleyandrew discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium AT laaksomarkku discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium AT pedersenoluf discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium AT koivistoveikko discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium AT ruettenhartmut discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium AT walkermark discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium AT pearsonewan discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium AT frankspaulw discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium AT discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium |